The mission of MHRP is to develop an HIV-1 vaccine, provide prevention, care, and treatment, and conduct meaningful HIV/AIDS research for the global community through the President's Emergency Plan for AIDS Relief (PEPFAR).
MHRP has ongoing studies and clinical trials using different types of MVA vaccines in Uganda and Thailand, with progress milestones including partial protection and viral load reduction in monkeys being infected with Simian Immunodeficiency Virus (SIV).
[18] According to the Henry M. Jackson Foundation for the Advancement of Military Medicine's 2016 annual report, MHRP works with local programs around the world to support more than 240,000 patients on antiretroviral therapy and to make HIV testing/advising accessible to more than 1.1 million people.
[19] Using existing in-country technical expertise and administrative infrastructure, MHRP expands partnerships with local researchers, health care services and NGOs in Africa to implement PEPFAR activities.
Additionally, MHRP conducted the first study to characterize that current clinical testing methods can have difficulty detecting HIV viral presence in persons with acute infections.
[21][22] Zika, Ebola, and Middle East Respiratory Syndrome (MERS) outbreaks were responded to by MHRP, as they used their infrastructure and research experience to help develop vaccines for both local people and military personnel living in regions where those diseases were endemic.
[24] In 2015, the Uganda site conducted a uniquely extensive study of Ebola survivors, finding that many were suffering from chronic malaise including hearing and vision loss up to 21 months post-infection.